Close Menu

NEW YORK (GenomeWeb) – CareDx reported after the close of the market on Wednesday that its third quarter revenues rose 74 percent year over year, thanks largely to a 6 percent increase in test volume for its AlloMap non-invasive blood test for heart transplant patients.

For the three months ended Sept. 30, the diagnostics company said revenues rose to $12.5 million from $7.2 million a year earlier, beating the average Wall Street analyst estimate of $11.5 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Economist reports that it is increasingly easier to analyze the metabolites people give off, potentially revealing personal information about them.

The Los Angeles Times reports that only a third of California students meet the state's new science standards.

A controversial paper on the gender gap in science has been corrected, according to BuzzFeed News.

In Science this week: evidence of interbreeding between the ancestors of West Africans and an unknown archaic human, and more.